One AI acquisition is being pulled apart after Beijing stepped in, adding a fresh risk to global tech dealmaking. One space name has real growth but is moving mostly on sector excitement, while one biotech stock is dealing with a small insider-sale notice after a big run. We’ll show you why all three stay in hold mode.
Crypto For Everyone (Sponsored)
Coinbase is built for people who want one crypto platform that can grow with them. If you’re just getting started, the app offers a beginner-friendly experience that makes it easier to explore the market, discover assets, and build steadily over time.
If you’re more advanced, Coinbase also offers more sophisticated trading tools designed for users who want deeper market access and more control.
Across one account, users can explore 300+ cryptocurrencies, automate their strategy with recurring buys, and stake eligible assets to earn rewards.
Coinbase also extends beyond trading with a self-custodial wallet for those who want to manage their own crypto and interact more directly with Web3.
The core appeal is simple: Coinbase combines ease of use with depth. It can serve as a first crypto platform for beginners while still offering advanced capabilities for more experienced users, all within one ecosystem.
Crypto assets are complex, volatile, and can result in loss of capital. Product availability varies.
Explore Coinbase’s all-in-one crypto platform today.
Futures at a Glance📈
Futures are pointing higher as global markets rally on signs of a possible U.S.-Iran peace deal. Oil is sliding after reports that the Strait of Hormuz could reopen, giving traders some relief after a tense week. The next big test is SpaceX’s Nasdaq debut, which could either fuel the risk-on mood or pull capital away from the rest of tech.
Want to make sure you never miss a pre-market alert?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.
Email’s great. Texts are faster.
You’ll be first in line when the market starts moving.
What to Watch
Earnings (Premarket):
• 51Talk Online Education Group [COE]
Earnings (Time Not Supplied):
• Sibanye Stillwater Limited [SBSW]
• High Templar Tech Limited [HTT]
• GDEV Inc. [GDEV]
• Waldencast plc [WALD]
• Enlivex Ltd. [ENLV]
• Bluerock Homes Trust, Inc. [BHM]
Economic Reports:
• U. Michigan Prelim Consumer Survey (Jun.): 10:00 am
Elite Trade Club Insider
A $42 Million Insider Split Just Hit Two Momentum Stocks
You’re seeing two charts that already moved, but you’re missing the part that matters most. Behind the tape, one major holder is preparing to unload stock near the top of a strong bank rally, while another heavyweight investor is buying more than $7.6 million of a biotech name after a massive run. Elite Trade Club Insider readers are getting the cleaner signal before the headline crowd catches up.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
Mega-Cap Tech
Meta Platforms Just Got a China Risk Reminder
Meta Platforms Inc (NASDAQ: META) is reportedly unwinding its $2 billion acquisition of Manus after Beijing ordered the deal reversed. According to the report, Meta has completed an operational split from Manus, told employees to stop using Manus tools for internal projects, and blocked Manus staff from accessing Meta’s internal data systems.
This matters because the issue is bigger than one deal. Beijing is tightening control over overseas transactions involving Chinese-linked technology, talent, and data. Manus had relocated its headquarters and core teams to Singapore, but Chinese regulators still stepped in.
That sends a clear warning to U.S. tech companies: AI assets with Chinese roots can carry regulatory risk even when the deal structure looks international.
For Meta, this is not large enough to break the broader thesis. The company still has a massive advertising engine, a large AI investment program, and a valuation around 21x earnings, which is not extreme for a mega-cap platform.
But it does add a new kind of uncertainty. Cross-border AI deals are becoming harder to price because technology transfer, talent movement, and data access can be challenged after the fact.
My Take For You: Meta’s core business is not defined by this Manus unwind, but the deal shows how messy global AI expansion is becoming. Investors should treat Chinese-linked AI assets as higher-risk until the rules are clearer.
My Verdict: Hold this. The risk is that tougher China rules limit Meta’s ability to acquire or integrate AI talent and technology across borders.
Space
Rocket Lab Is Getting a SpaceX Halo, but the Stock Has Already Moved Fast
Rocket Lab Corp (NASDAQ: RKLB) jumped as space stocks rallied around renewed SpaceX IPO chatter. Shares finished regular trading up more than 9% and moved higher after hours, even though there was no major company-specific news behind the move.
Traders were buying fast-growing aerospace and defense names as SpaceX’s expected public-market debut brought attention back to the sector.
Rocket Lab does have real operating progress underneath the excitement. First-quarter revenue rose 63.5% year over year to $200.3 million, GAAP gross margin reached a record 38.2%, and backlog climbed to $2.2 billion with more than 70 missions on the books. The company also guided second-quarter revenue to $225 million to $240 million.
The next key company-specific milestone is Neutron. CFO Adam Spice said Neutron could take a “very nice spot” in the launch market as SpaceX focuses on Starlink, Starship, and possibly space-based data centers.
Rocket Lab still aims to launch Neutron before the end of the year, despite a prior testing setback. That gives investors a real catalyst, but the stock is already up more than 330% over the past year and trades above the average analyst target.
My Take For You: Rocket Lab has strong growth, a large backlog, and a real Neutron catalyst, but the latest move is mostly sector excitement. The stock needs execution to catch up with the price.
My Verdict: Hold this. The risk is that SpaceX IPO enthusiasm fades before Rocket Lab delivers its next major milestone.
A New Warning (Sponsored)
Whitney Tilson shocked the nation on 60 Minutes when he accused a major company of poisoning its customers.
The investigation won an Emmy and the stock fell nearly 80%. (He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers).
Now, he's releasing his next big story. He says a dangerous pattern is forming, and most Americans have no idea how exposed they really are.
For the full presentation, go here.
Biotech
Adaptive Biotechnologies Has Insider Sale Noise, but Not a Thesis-Changing Signal
Adaptive Biotechnologies Corp (NASDAQ: ADPT) is moving higher after a strong run, but the latest filing is more noise than a major warning. The company filed a Form 144 notice for a proposed brokered sale of 5,000 shares of common stock through Morgan Stanley Smith Barney, with a listed value of $85,350 and an associated date of June 11, 2026.
The filing also disclosed recent 10b5-1 sales by Susan Bobulsky of 11,000 shares on June 4 for $198,000. These transactions are worth watching, but they are small relative to the company’s broader share count. The filing listed roughly 160 million shares outstanding, which means the proposed sale is not material by itself.
The bigger setup is that the stock has already had a strong move, up nearly 80% over the past year and trading close to its 52-week high.
That makes even small insider-sale notices more visible to traders. But a Form 144 is a notice of intent to sell, not a completed sale, and the size here does not suggest a major confidence break.
My Take For You: Adaptive’s insider filing is worth noting, but it is not large enough to change the story. After a big run, the stock needs business execution more than filing noise.
My Verdict: Hold this. The risk is that more insider selling appears while the stock is already extended near recent highs.
Poll: Which type of stock tends to outperform most consistently in the early phase of a new bull market?
Movers and Shakers
Alamar Biosciences [ALMR]: Premarket Move: -10%
Alamar is pulling back despite Stifel reiterating a Buy rating and $28 price target. The bullish case is still tied to its Argo platform, growing instrument adoption, and the new CNS 220 panel, especially in Alzheimer’s and neuro applications.
The issue is valuation. Alamar is still unprofitable, and investors are getting more selective with early-stage life-science tools names.
My Take: Watch it, but do not chase. The platform has promise, but the stock needs stronger adoption data before this dip becomes buyable.
Firefly Aerospace [FLY]: Premarket Move: +6%
Firefly is moving higher after winning a $75 million NASA JPL MoonFall subcontract to deliver four drones to the Moon’s south pole using its Elytra spacecraft. The stock is also getting help from renewed space-stock momentum tied to SpaceX IPO excitement.
The growth ramp is big. Firefly posted $80.9 million in Q1 revenue and guided for $420 million to $450 million in 2026 revenue. But it also lost about $96.7 million in the quarter, so this is still a high-burn story.
My Take: Buy this. Firefly has real contract momentum, a major NASA win, and a clear revenue ramp. The losses are still heavy, but this is one of the stronger speculative space names to own on weakness.
NuScale Power [SMR]: Premarket Move: +6%
NuScale is rising as investors revisit the small modular reactor trade. The company still has roughly $1 billion in liquidity and remains the only SMR developer with a U.S. NRC-approved design.
The long-term story is attractive, with up to 6 GW of planned U.S. nuclear capacity through the ENTRA1/TVA framework and progress in Romania. The catch is timing. BofA resumed coverage at Neutral with a $12 target, flagging slow contract conversion and revenue pushed into the early 2030s.
My Take: Hold for patient speculation, but do not chase. NuScale has a strong nuclear narrative, but the revenue timeline is still too far out.
Income Strategy (Sponsored)
His official paycheck? $400,000 a year.
But the real story is somewhere else:
As much as $250,000 per month… from a single source.
It’s not real estate. It’s not the stock market.
So what’s actually producing this level of cash flow — and why are more investors turning to it today?
Discover how to get started for less than $20.
Everything Else
📈 Big-money accumulation is starting to stand out, as Wall Street funnels fresh capital into stocks showing the kind of tape action that often precedes a larger run.
🛢️ Iran is reportedly floating a peace memo that could ease pressure around sanctions, oil flows, and the Strait of Hormuz.
🤖 ChatGPT keeps pulling in massive app traffic, even as public sentiment around AI adoption gets more complicated.
🚀 SpaceX reportedly cut its retail IPO allocation to the low-20% range, giving institutions a bigger slice of the listing pie.
🧠 Nvidia has started pitching its Vera CPU to Chinese clients as the chip giant looks for another China workaround.
🏭 TSMC’s boss is warning that Taiwan’s chip industry needs more talent, water, and supply support.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
